UpToDate on eosinophils

Abstract

This review describes the eosinophil journey through the various physiological and pathophysiological phases, from production, maturation, and activation by chemokines and cytokines [especially eotaxin, interleukin (IL)-5, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF)], to interaction with the innate and adaptive immune system and tissue homing. Excessive production and activation of eosinophils lead to the release of granule proteins, such as major basic protein, eosinophil cationic protein, eosinophil peroxidase, and others, resulting in inflammation, cell cytotoxicity, and oxidative stress. The pathogenesis, clinical features, diagnostic processes, and the latest therapeutic approaches to the resulting diseases—which affect the upper and lower airways, gastrointestinal tract, skin, myocardium, and may occur systemically—are discussed.

Keywords

regulatory vs. inflammatory eosinophils / allergic rhinitis / CRSwNP / asthma / COPD / EGPA / ABPA / eosinophilic esophagitis / eosinophilic myocarditis / eosinophilic pneumonia / DRESS / urticaria

References

[1] Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013; 13:9-22.

[2] Simon HU. The eosinophil and its role in physiology and disease: news and views. Semin Immunopathol. 2021; 43:291-3.

[3] Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014; 289:17406—15.

[4] Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature. 2012; 484:465—72.

[5] Chusid MJ. Eosinophils: Friends or Foes? J Allergy Clin Immunol Pract. 2018; 6:1439—44.

[6] Adamko D, Lacy P, Moqbel R. Mechanisms of eosinophil recruitment and activation. Curr Allergy Asthma Rep. 2002; 2:107-16.

[7] Kita H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev. 2011; 242:161-77.

[8] Aoki A, Hirahara K, Kiuchi M, Nakayama T. Eosinophils: Cells known for over 140 years with broad and new functions. Allergol Int. 2021; 70:3-8.

[9] Long H, Liao W, Wang L, Lu Q. A Player and Coordinator: The Versatile Roles of Eosinophils in the Immune System. Transfus Med Hemother. 2016; 43:96-108.

[10] Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic—associated inflammatory conditions. Curr Res Immunol. 2022; 3:42-53.

[11] Weller PF. The immunobiology of eosinophils. N Engl J Med. 1991; 324:1110—8.

[12] Gigon L, Fettrelet T, Yousefi S, Simon D, Simon HU. Eosinophils from A to Z. Allergy. 2023; 78:1810—46.

[13] Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006; 24:147-74.

[14] Abdala—Valencia H, Coden ME, Chiarella SE, Jacobsen EA, Bochner BS, Lee JJ, et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J Leukoc Biol. 2018; 104:95-108.

[15] Wechsler ME, Munitz A, Ackerman SJ, Drake MG, Jackson DJ, Wardlaw AJ, et al. Eosinophils in Health and Disease: A State—of—the—Art Review. Mayo Clin Proc. 2021; 96:2694-707.

[16] Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol. 2014; 5:570.

[17] Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008; 38:709—50.

[18] Dvorak AM, Furitsu T, Letourneau L, Ishizaka T, Ackerman SJ. Mature eosinophils stimulated to develop in human cord blood mononuclear cell cultures supplemented with recombinant human interleukin—5. Part I. Piecemeal degranulation of specific granules and distribution of Charcot—Leyden crystal protein. Am J Pathol. 1991; 138:69-82.

[19] Spencer LA, Bonjour K, Melo RCN, Weller PF. Eosinophil secretion of granule—derived cytokines. Front Immunol. 2014; 5:496.

[20] Peters MS, Rodriguez M, Gleich GJ. Localization of human eosinophil granule major basic protein, eosinophil cationic protein, and eosinophil—derived neurotoxin by immunoelectron microscopy. Lab Invest. 1986; 54:656—62.

[21] Lacy P, Moqbel R. Signaling and Degranulation. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. New York: Elsevier; 2013. pp. 206—19.

[22] Walsh GM. Eosinophil granule proteins and their role in disease. Curr Opin Hematol. 2001; 8:28-33.

[23] Lacy P, Nair P. The Human Eosinophil. In: Greer JP, Rodgers GM, Glader B, Arber DA, Means RT, List AF, et al., editors. Wintrobe’s Clinical Hematology. 14th ed. Philadelphia: Wolters Kluwer; 2019. pp. 167-90.

[24] Erjefält JS, Persson CG. New aspects of degranulation and fates of airway mucosal eosinophils. Am J Respir Crit Care Med. 2000; 161:2074-85.

[25] Saffari H, Hoffman LH, Peterson KA, Fang JC, Leiferman KM, Pease LF 3rd, et al. Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2014; 133:1728-34.e1.

[26] Radonjic—Hoesli S, Wang X, de Graauw E, Stoeckle C, Styp—Rekowska B, Hlushchuk R, et al. Adhesion—induced eosinophil cytolysis requires the receptor—interacting protein kinase 3 (RIPK3)—mixed lineage kinase—like (MLKL) signaling pathway, which is counterregulated by autophagy. J Allergy Clin Immunol. 2017; 140:1632—42.

[27] Mazzeo C, Cañas JA, Zafra MP, Rojas Marco A, Fernández—Nieto M, Sanz V, et al. Exosome secretion by eosinophils: A possible role in asthma pathogenesis. J Allergy Clin Immunol. 2015; 135:1603—13.

[28] Cañas JA, Sastre B, Rodrigo—Muñoz JM, Del Pozo V. Exosomes: A new approach to asthma pathology. Clin Chim Acta. 2019; 495:139—47.

[29] Weihrauch T, Melo RCN, Gray N, Voehringer D, Weller PF, Raap U. Eosinophil extracellular vesicles and DNA traps in allergic inflammation. Front Allergy. 2024; 5:1448007.

[30] Driss V, Legrand F, Capron M. Eosinophil Receptor Profile. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Heatlh and Disease. New York: Elsevier; 2013. pp. 30-8.

[31] Adamko DJ, Wu Y, Gleich GJ, Lacy P, Moqbel R. The induction of eosinophil peroxidase release: improved methods of measurement and stimulation. J Immunol Methods. 2004; 291:101—8.

[32] Melo RCN, Perez SAC, Spencer LA, Dvorak AM, Weller PF. Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. Traffic. 2005; 6:866-79.

[33] Melo RCN, Weller PF. Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses. Histol Histopathol. 2010; 25:1341—54.

[34] Lacy P, Mahmudi—Azer S, Bablitz B, Hagen SC, Velazquez JR, Man SF, et al. Rapid mobilization of intracellularly stored RANTES in response to interferon—gamma in human eosinophils. Blood. 1999; 94:23-32.

[35] Spencer LA, Melo RCN, Perez SAC, Bafford SP, Dvorak AM, Weller PF. Cytokine receptor—mediated trafficking of preformed IL—4 in eosinophils identifies an innate immune mechanism of cytokine secretion. Proc Natl Acad Sci U S A. 2006; 103:3333-8.

[36] Lacy P, Willetts L, Kim JD, Lo AN, Lam B, Maclean EI, et al. Agonist activation of f—actin—mediated eosinophil shape change and mediator release is dependent on Rac2. Int Arch Allergy Immunol. 2011; 156:137-47.

[37] Lacy P, Logan MR, Bablitz B, Moqbel R. Fusion protein vesicle—associated membrane protein 2 is implicated in IFN—gamma—induced piecemeal degranulation in human eosinophils from atopic individuals. J Allergy Clin Immunol. 2001; 107:671—8.

[38] Logan MR, Lacy P, Bablitz B, Moqbel R . Expression of eosinophil target SNAREs as potential cognate receptors for vesicle—associated membrane protein—2 in exocytosis. J Allergy Clin Immunol. 2002; 109:299-306.

[39] Logan MR, Lacy P, Odemuyiwa SO, Steward M, Davoine F, Kita H, et al. A critical role for vesicle—associated membrane protein—7 in exocytosis from human eosinophils and neutrophils. Allergy. 2006; 61:777-84.

[40] Kim JD, Willetts L, Ochkur S, Srivastava N, Hamburg R, Shayeganpour A, et al. An essential role for Rab27a GTPase in eosinophil exocytosis. J Leukoc Biol. 2013; 94:1265—74.

[41] Gentil K, Hoerauf A, Layland LE. Eosinophil—Mediated Responses Toward Helminths. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. New York: Elsevier; 2013. pp. 303—12.

[42] Foster PS, Rosenberg HF, Asquith KL, Kumar RK. Targeting eosinophils in asthma. Curr Mol Med. 2008; 8:585-90.

[43] Nutman TB. Immune Responses in Helminth Infections. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. New York: Elsevier; 2013. pp. 312—20.

[44] Rosenberg HF, Dyer KD, Domachowske JB. Interactions of Eosinophils with Respiratory Virus Pathogens. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. New York: Elsevier; 2013. pp. 281-90.

[45] Huang L, Appleton JA. Eosinophils in Helminth Infection: Defenders and Dupes. Trends Parasitol. 2016; 32:798-807.

[46] Yousefi S, Simon D, Simon HU. Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol. 2012; 24:736—9.

[47] Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007; 119:1303—10.

[48] Sanchez Santos A, Socorro Avila I, Galvan Fernandez H, Cazorla Rivero S, Lemes Castellano A, Cabrera Lopez C . Eosinophils: old cells, new directions. Front Med (Lausanne). 2025; 11:1470381.

[49] Matsumoto K, Bochner BS. Adhesion molecules. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. New York: Elsevier; 2013. pp. 131—9.

[50] Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol. 2009; 101:81-121.

[51] Jacobsen EA, Helmers RA, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood. 2012; 120:3882-90.

[52] Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm. 2015; 2015:879783.

[53] Walsh GM. Eosinophil apoptosis and clearance in asthma. J Cell Death. 2013; 6:17-25.

[54] Nissim Ben Efraim AH, Levi—Schaffer F . Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis. 2008; 2:163-71.

[55] Cheung PFY, Wong CK, Ip WK, Lam CWK. IL—25 regulates the expression of adhesion molecules on eosinophils: mechanism of eosinophilia in allergic inflammation. Allergy. 2006; 61:878—85.

[56] Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, et al. Interleukin—33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest. 2008; 88:1245—53.

[57] Wong CK, Hu S, Cheung PFY, Lam CWK. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol. 2010; 43:305—15.

[58] Walsh GM, Symon FA, Wardlaw AJ. Human eosinophils preferentially survive on tissue fibronectin compared with plasma fibronectin. Clin Exp Allergy. 1995; 25:1128-36.

[59] Weller PF, Spencer LA. Functions of tissue—resident eosinophils. Nat Rev Immunol. 2017; 17:746-60.

[60] Whitehead GS, Thomas SY, Shalaby KH, Nakano K, Moran TP, Ward JM, et al. TNF is required for TLR ligand—mediated but not protease—mediated allergic airway inflammation. J Clin Invest. 2017; 127:3313—26.

[61] Hong GH, Kwon HS, Lee KY, Ha EH, Moon KA, Kim SW, et al. hMSCs suppress neutrophil—dominant airway inflammation in a murine model of asthma. Exp Mol Med. 2017; 49:e288.

[62] Hirakata T, Lee HC, Ohba M, Saeki K, Okuno T, Murakami A, et al. Dietary ω—3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating T_h2 immune responses . FASEB J. 2019; 33:3392-403.

[63] Xu L, Tian D, Zhou M, Ma J, Sun G, Jin H, et al. OX40 Expression in Eosinophils Aggravates OVA—Induced Eosinophilic Gastroenteritis. Front Immunol. 2022; 13:841141.

[64] Malacco NLSO, Rachid MA, Gurgel ILDS, Moura TR, Sucupira PHF, de Sousa LP, et al. Eosinophil—Associated Innate IL—17 Response Promotes Aspergillus fumigatus Lung Pathology . Front Cell Infect Microbiol. 2019; 8:453.

[65] Zhang D, Yang J, Zhao Y, Shan J, Wang L, Yang G, et al. RSV Infection in Neonatal Mice Induces Pulmonary Eosinophilia Responsible for Asthmatic Reaction. Front Immunol. 2022; 13:817113.

[66] Chambers ED, White A, Vang A, Wang Z, Ayala A, Weng T, et al. Blockade of equilibrative nucleoside transporter 1/2 protects against Pseudomonas aeruginosa—induced acute lung injury and NLRP3 inflammasome activation. FASEB J. 2020; 34:1516-31.

[67] Jiao D, Wong CK, Qiu HN, Dong J, Cai Z, Chu M, et al. NOD2 and TLR2 ligands trigger the activation of basophils and eosinophils by interacting with dermal fibroblasts in atopic dermatitis—like skin inflammation. Cell Mol Immunol. 2016; 13:535—50.

[68] Scheunemann JF, Reichwald JJ, Korir PJ, Kuehlwein JM, Jenster LM, Hammerschmidt—Kamper C, et al. Eosinophils Suppress the Migration of T Cells Into the Brain of Plasmodium berghei—Infected Ifnar1^—/— Mice and Protect Them From Experimental Cerebral Malaria . Front Immunol. 2021; 12:711876.

[69] Liou CJ, Chen YL, Yu MC, Yeh KW, Shen SC, Huang WC. Sesamol Alleviates Airway Hyperresponsiveness and Oxidative Stress in Asthmatic Mice. Antioxidants (Basel). 2020; 9:295.

[70] Badrani JH, Strohm AN, Lacasa L, Civello B, Cavagnero K, Haung YA, et al. RNA—binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation and inflammation partially through CysLT1R. Nat Commun. 2022; 13:4435.

[71] Rudulier CD, Tonti E, James E, Kwok WW, Larché M. Modulation of CRTh2 expression on allergen—specific T cells following peptide immunotherapy. Allergy. 2019; 74:2157—66.

[72] Jackson DJ, Makrinioti H, Rana BMJ, Shamji BWH, Trujillo—Torralbo MB, Footitt J, et al. IL—33—dependent type 2 inflammation during rhinovirus—induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014; 190:1373-82.

[73] Subramanian H, Hashem T, Bahal D, Kammala AK, Thaxton K, Das R. Ruxolitinib Ameliorates Airway Hyperresponsiveness and Lung Inflammation in a Corticosteroid—Resistant Murine Model of Severe Asthma. Front Immunol. 2021; 12:786238.

[74] Shamri R, Young KM, Weller PF. Rho and Rac, but not ROCK, are required for secretion of human and mouse eosinophil—associated RNases. Clin Exp Allergy. 2019; 49:190-8.

[75] Hattori K, Tanaka S, Hashiba D, Tamura J, Etori K, Kageyama T, et al. Synovial regulatory T cells expressing ST2 deteriorate joint inflammation through the suppression of immunoregulatory eosinophils. J Autoimmun. 2024; 149:103333.

[76] Majumder S, Bhattacharjee A, Paul Chowdhury B, Bhattacharyya Majumdar S, Majumdar S. Antigen—Pulsed CpG—ODN—Activated Dendritic Cells Induce Host—Protective Immune Response by Regulating the T Regulatory Cell Functioning in Leishmania donovani—Infected Mice: Critical Role of CXCL10. Front Immunol. 2014; 5:261.

[77] Andreev D, Kachler K, Liu M, Chen Z, Krishnacoumar B, Ringer M, et al. Eosinophils preserve bone homeostasis by inhibiting excessive osteoclast formation and activity via eosinophil peroxidase. Nat Commun. 2024; 15:1067.

[78] Fitzpatrick AM, Park Y, Brown LAS, Jones DP. Children with severe asthma have unique oxidative stress—associated metabolomic profiles. J Allergy Clin Immunol. 2014; 133:258-61.

[79] Wang F, Trier AM, Li F, Kim S, Chen Z, Chai JN, et al. A basophil—neuronal axis promotes itch. Cell. 2021; 184:422—40.

[80] Takahashi Y, Kobayashi T, D’Alessandro—Gabazza CN, Toda M, Fujiwara K, Okano T, et al. Protective Role of Matrix Metalloproteinase—2 in Allergic Bronchial Asthma. Front Immunol. 2019; 10:1795.

[81] Kanemitsu Y, Suzuki M, Fukumitsu K, Asano T, Takeda N, Nakamura Y, et al. A novel pathophysiologic link between upper and lower airways in patients with chronic rhinosinusitis: Association of sputum periostin levels with upper airway inflammation and olfactory function. World Allergy Organ J. 2020; 13:100094.

[82] Wildering WC, Hermann PM, Bulloch AGM. Rapid neuromodulatory actions of integrin ligands. J Neurosci. 2002; 22:2419-26.

[83] Barillaro M, Schuurman M, Wang R. Collagen IV—β1—Integrin Influences INS—1 Cell Insulin Secretion via Enhanced SNARE Protein Expression. Front Cell Dev Biol. 2022; 10:894422.

[84] Vadakumchery A, Faraidun H, Ayoubi OE, Outaleb I, Schmid V, Abdelrasoul H, et al. The Small GTPase RHOA Links SLP65 Activation to PTEN Function in Pre B Cells and Is Essential for the Generation and Survival of Normal and Malignant B Cells. Front Immunol. 2022; 13:842340.

[85] Janulaityte I, Januskevicius A, Rimkunas A, Palacionyte J, Vitkauskiene A, Malakauskas K. Asthmatic Eosinophils Alter the Gene Expression of Extracellular Matrix Proteins in Airway Smooth Muscle Cells and Pulmonary Fibroblasts. Int J Mol Sci. 2022; 23:4086.

[86] Kim S, Nam H, Cha B, Park J, Sung HJ, Jeon JS. Acoustofluidic Stimulation of Functional Immune Cells in a Microreactor. Adv Sci (Weinh). 2022; 9:2105809.

[87] Andreone S, Spadaro F, Buccione C, Mancini J, Tinari A, Sestili P, et al. IL—33 Promotes CD11b/CD18—Mediated Adhesion of Eosinophils to Cancer Cells and Synapse—Polarized Degranulation Leading to Tumor Cell Killing. Cancers (Basel). 2019; 11:1664.

[88] Drake LY, Iijima K, Bartemes K, Kita H. Group 2 Innate Lymphoid Cells Promote an Early Antibody Response to a Respiratory Antigen in Mice. J Immunol. 2016; 197:1335—42.

[89] Kephart GM, Alexander JA, Arora AS, Romero Y, Smyrk TC, Talley NJ, et al. Marked deposition of eosinophil—derived neurotoxin in adult patients with eosinophilic esophagitis. Am J Gastroenterol. 2010; 105:298-307.

[90] Kobayashi Y, Kanda A, Yun Y, Dan Van B, Suzuki K, Sawada S, et al. Reduced Local Response to Corticosteroids in Eosinophilic Chronic Rhinosinusitis with Asthma. Biomolecules. 2020; 10:326.

[91] Kim H, Youn GS, An SY, Kwon HY, Choi SY, Park J. 2,3—Dimethoxy—2'—hydroxychalcone ameliorates TNF—α—induced ICAM—1 expression and subsequent monocyte adhesiveness via NF—kappaB inhibition and HO—1 induction in HaCaT cells. BMB Rep. 2016; 49:57-62.

[92] Pavord ID, Bel EH, Bourdin A, Chan R, Han JK, Keene ON, et al. From DREAM to REALITI—A and beyond: Mepolizumab for the treatment of eosinophil—driven diseases. Allergy. 2022; 77:778-97.

[93] Walsh GM. Reslizumab in the treatment of severe eosinophilic asthma: an update. Immunotherapy. 2018; 10:695-8.

[94] Zhu M, Yang J, Chen Y. Efficacy and safety of treatment with benralizumab for eosinophilic asthma. Int Immunopharmacol. 2022; 111:109131.

[95] Maselli DJ, Rogers L, Peters JI. Benralizumab, an add—on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use. Ther Clin Risk Manag. 2018; 14:2059-68.

[96] Gauvreau GM, Sehmi R, FitzGerald JM, Leigh R, Cockcroft DW, Davis BE, et al. Benralizumab for allergic asthma: a randomised, double—blind, placebo—controlled trial. Eur Respir J. 2024; 64:2400512.

[97] Toussaint M, Jackson DJ, Swieboda D, Guedán A, Tsourouktsoglou TD, Ching YM, et al. Host DNA released by NETosis promotes rhinovirus—induced type—2 allergic asthma exacerbation. Nat Med. 2017; 23:681—91.

[98] Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010; 40:563-75.

[99] Akuthota P, Wang HB, Spencer LA, Weller PF. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clin Exp Allergy. 2008; 38:1254-63.

[100] Farhan RK, Vickers MA, Ghaemmaghami AM, Hall AM, Barker RN, Walsh GM. Effective antigen presentation to helper T cells by human eosinophils. Immunology. 2016; 149:413—22.

[101] Wang HB, Weller PF. Pivotal advance: eosinophils mediate early alum adjuvant—elicited B cell priming and IgM production. J Leukoc Biol. 2008; 83:817—21.

[102] Chu VT, Fröhlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011; 12:151-9.

[103] Wu D, Molofsky AB, Liang HE, Ricardo—Gonzalez RR, Jouihan HA, Bando JK, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011; 332:243—7.

[104] Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, et al. Eosinophil—derived neurotoxin acts as an alarmin to activate the TLR2—MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med. 2008; 205:79-90.

[105] Minai—Fleminger Y, Levi—Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm Res. 2009; 58:631—8.

[106] Haskell MD, Moy JN, Gleich GJ, Thomas LL. Analysis of signaling events associated with activation of neutrophil superoxide anion production by eosinophil granule major basic protein. Blood. 1995; 86:4627—37.

[107] Rosenberg HF, Dyer KD, Domachowske JB. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res. 2009; 83:1-9.

[108] Samarasinghe AE, Melo RCN, Duan S, LeMessurier KS, Liedmann S, Surman SL, et al. Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus. J Immunol. 2017; 198:3214—26.

[109] Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, et al. Catapult—like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med. 2008; 14:949-53.

[110] Gaur P, Zaffran I, George T, Rahimli Alekberli F, Ben—Zimra M, Levi—Schaffer F. The regulatory role of eosinophils in viral, bacterial, and fungal infections. Clin Exp Immunol. 2022; 209:72-82.

[111] Linch SN, Danielson ET, Kelly AM, Tamakawa RA, Lee JJ, Gold JA. Interleukin 5 is protective during sepsis in an eosinophil—independent manner. Am J Respir Crit Care Med. 2012; 186:246-54.

[112] Herbst T, Sichelstiel A, Schär C, Yadava K, Bürki K, Cahenzli J, et al. Dysregulation of allergic airway inflammation in the absence of microbial colonization. Am J Respir Crit Care Med. 2011; 184:198-205.

[113] Bisgaard H, Li N, Bonnelykke K, Chawes BLK, Skov T, Paludan—Müller G, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011; 128:646—52.

[114] Ramirez GA, Yacoub MR, Ripa M, Mannina D, Cariddi A, Saporiti N, et al. Eosinophils from Physiology to Disease: A Comprehensive Review. Biomed Res Int. 2018; 2018:9095275.

[115] Diny NL, Yamada Y, Zimmermann N. Editorial: Update on eosinophil—associated diseases. Front Allergy. 2025; 6:1740057.

[116] Travers J, Rothenberg ME. Eosinophils in mucosal immune responses. Mucosal Immunol. 2015; 8:464-75.

[117] Kurihara S, Suzuki K, Yokota M, Ito T, Hayashi Y, Kikuchi R, et al. Eosinophils Contribute to Oral Tolerance via Induction of RORγt—Positive Antigen—Presenting Cells and RORγt—Positive Regulatory T Cells. Biomolecules. 2024; 14:89.

[118] Sasaki H, Miyata J, Kawana A, Fukunaga K. Antiviral roles of eosinophils in asthma and respiratory viral infection. Front Allergy. 2025; 6:1548338.

[119] Goh YPS, Henderson NC, Heredia JE, Red Eagle A, Odegaard JI, Lehwald N, et al. Eosinophils secrete IL—4 to facilitate liver regeneration. Proc Natl Acad Sci U S A. 2013; 110:9914—9.

[120] Xie L, Zhang H, Xu L. The Role of Eosinophils in Liver Disease. Cell Mol Gastroenterol Hepatol. 2025; 19:101413.

[121] Di Gioacchino M, Della Valle L, Allegra A, Pioggia G, Gangemi S. AllergoOncology: Role of immune cells and immune proteins. Clin Transl Allergy. 2022; 12:e12133.

[122] Tomii T, Kano G. Eosinophils in inflammatory bowel disease pathogenesis: an ROS—centric view. Front Allergy. 2025; 6:1608202.

[123] Jung Y, Wen T, Mingler MK, Caldwell JM, Wang YH, Chaplin DD, et al. IL—1β in eosinophil—mediated small intestinal homeostasis and IgA production. Mucosal Immunol. 2015; 8:930-42.

[124] Fulkerson PC. Transcription Factors in Eosinophil Development and As Therapeutic Targets. Front Med (Lausanne). 2017; 4:115.

[125] Masterson JC, Menard—Katcher C, Larsen LD, Furuta GT, Spencer LA. Heterogeneity of Intestinal Tissue Eosinophils: Potential Considerations for Next—Generation Eosinophil—Targeting Strategies. Cells. 2021; 10:426.

[126] Van Hulst G, Bureau F, Desmet CJ. Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity? Int J Mol Sci. 2021; 22:10150.

[127] Goasguen JE, Bennett JM, Bain BJ, Brunning R, Zini G, Vallespi MT, et al. ; International Working Group on Morphology of MDS. The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm. Br J Haematol. 2020; 191:497-504.

[128] Novosad J, Krčmová I, Souček O, Drahošová M, Sedlák V, Kulířová M, et al. Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment. Int J Mol Sci. 2023; 24:5716.

[129] Sastre B, Rodrigo—Muñoz JM, Garcia—Sanchez DA, Cañas JA, Del Pozo V. Eosinophils: Old players in a new game. J Investig Allergol Clin Immunol. 2018; 28:289-304.

[130] Kanda A, Yun Y, Bui DV, Nguyen LM, Kobayashi Y, Suzuki K, et al. The multiple functions and subpopulations of eosinophils in tissues under steady—state and pathological conditions. Allergol Int. 2021; 70:9-18.

[131] Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, et al. Lung—resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016; 126:3279-95.

[132] Day KS, Rempel L, Rossi FMV, Theret M. Origins and functions of eosinophils in two non—mucosal tissues. Front Immunol. 2024; 15:1368142.

[133] Gupta K, Falta NA, Spencer LA. Innate Immune Pairing: Eosinophils as Hidden Architects of T Cell Immunity. Cells. 2025; 14:1826.

[134] Gurtner A, Crepaz D, Arnold IC. Emerging functions of tissue—resident eosinophils. J Exp Med. 2023; 220:e20221435.

[135] Arnold IC. Adapting to their new home: Eosinophils remodel the gut architecture. J Exp Med. 2022; 219:e20220146.

[136] Not All Eosinophils Are the Same [Internet]. Immunopaedia.org.za; c2004— 2026 [cited 2026 Jan 12]. Available from: https://www.immunopaedia.org.za/breaking—news/not—all—eosinophils—are—the—same/#:~:text=This%20integrated%20approach%20allowed%20the,a%20unified%20model%20in%20

[137] Hu Y, Wu L, Qu S, Kong WT, Yu X, Xu J, et al. Temporal and spatial atlas of eosinophil specialization across tissues. Nat Immunol. 2026;[Epub ahead of print].

[138] Mehta P, Furuta GT. Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am. 2015; 35:413—37.

[139] Raap U, Wardlaw AJ. A new paradigm of eosinophil granulocytes: neuroimmune interactions. Exp Dermatol. 2008; 17:731—8.

[140] Janson C, Bjermer L, Lehtimäki L, Kankaanranta H, Karjalainen J, Altraja A, et al. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges. Eur Clin Respir J. 2022; 9:2040707.

[141] Mormile M, Mormile I, Fuschillo S, Rossi FW, Lamagna L, Ambrosino P, et al. Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice. Int J Mol Sci. 2023; 24:7254.

[142] Gevaert P, Han JK, Smith SG, Sousa AR, Howarth PH, Yancey SW, et al. The roles of eosinophils and interleukin—5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022; 12:1413-23.

[143] Giombi F, Pace GM, Pirola F, Cerasuolo M, Ferreli F, Mercante G, et al. Airways Type—2 Related Disorders: Multiorgan, Systemic or Syndemic Disease? Int J Mol Sci. 2024; 25:730.

[144] Costanzo G, Costanzo GAML, Del Moro L, Nappi E, Pelaia C, Puggioni F, et al. Mast Cells in Upper and Lower Airway Diseases: Sentinels in the Front Line. Int J Mol Sci. 2023; 24:9771.

[145] Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects. Thorax. 2000; 55 Suppl 2:S26-7.

[146] Tiotiu A, Novakova P, Baiardini I, Bikov A, Chong—Neto H, de—Sousa JC, et al. Manifesto on united airways diseases (UAD): an Interasma (global asthma association—GAA) document. J Asthma. 2022; 59:639—54.

[147] Giunta G, Pirola F, Giombi F, Muci G, Pace GM, Heffler E, et al. Care for Patients with Type—2 Chronic Rhinosinusitis. J Pers Med. 2023; 13:618.

[148] Ogulur I, Mitamura Y, Yazici D, Pat Y, Ardicli S, Li M, et al. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025; 22:211-42.

[149] Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021; 21:739—51.

[150] Shin SH, Ye MK, Park J, Geum SY. Immunopathologic Role of Eosinophils in Eosinophilic Chronic Rhinosinusitis. Int J Mol Sci. 2022; 23:13313.

[151] Tu Z, Liu M, Xu C, Wei Y, Lu T, Xiao Y, et al. Functional 2D Nanoplatforms Alleviate Eosinophilic Chronic Rhinosinusitis by Modulating Eosinophil Extracellular Trap Formation. Adv Sci (Weinh). 2024; 11:e2307800.

[152] Cha H, Lim HS, Park J, Jo A, Ryu HT, Kim DW, et al. Effects of Neutrophil and Eosinophil Extracellular Trap Formation on Refractoriness in Chronic Rhinosinusitis With Nasal Polyps. Allergy Asthma Immunol Res. 2023; 15:94-108.

[153] Eng SS, DeFelice ML. The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review. Clin Rev Allergy Immunol. 2016; 50:140—58.

[154] Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58:1-464.

[155] Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020; 6:86.

[156] Toppila—Salmi S, Reitsma S, Hox V, Gane S, Eguiluz—Gracia I, Shamji M, et al. Endotyping in Chronic Rhinosinusitis—An EAACI Task Force Report. Allergy. 2025; 80:132-47.

[157] Asano K, Ueki S, Tamari M, Imoto Y, Fujieda S, Taniguchi M. Adult—onset eosinophilic airway diseases. Allergy. 2020; 75:3087-99.

[158] Banerji A, Piccirillo JF, Thawley SE, Levitt RG, Schechtman KB, Kramper MA, et al. Chronic rhinosinusitis patients with polyps or polypoid mucosa have a greater burden of illness. Am J Rhinol. 2007; 21:19-26.

[159] Marino MJ, Garcia JO, Zarka MA, Lal D. Inflammatory cell predominance and patterns in chronic rhinosinusitis with and without nasal polyposis patients. Laryngoscope Investig Otolaryngol. 2019; 4:573—7.

[160] Alobid I, Armengot—Carceller M, Pinilla Urraca M, Maza—Solano J, González Guijarro I, Umbria Jiménez S, et al. When the Nose Meets the Lab: Histopathological Analysis in Chronic Rhinosinusitis with Nasal Polyps for Routine Clinical Practice. Curr Allergy Asthma Rep. 2024; 24:657—65.

[161] Bochner BS, Stevens WW. Biology and Function of Eosinophils in Chronic Rhinosinusitis With or Without Nasal Polyps. Allergy Asthma Immunol Res. 2021; 13:8-22.

[162] Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. J Asthma Allergy. 2021; 14:127—34.

[163] McHugh T, Snidvongs K, Xie M, Banglawala S, Sommer D. High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta—analysis. Int Forum Allergy Rhinol. 2018; 8:1421—9.

[164] Cho SH, Hamilos DL, Han DH, Laidlaw TM. Phenotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2020; 8:1505—11.

[165] Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin—exacerbated respiratory disease among asthmatic patients: A meta—analysis of the literature. J Allergy Clin Immunol. 2015; 135:676-81.

[166] Cavagnero KJ, Doherty TA. Lipid—mediated innate lymphoid cell recruitment and activation in aspirin—exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2021; 126:135-42.

[167] Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin—Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2017; 5:1061—70.

[168] Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. ; World Health Organization; GA(2)LEN, AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008; 63:8-160.

[169] Ciprandi G, Vizzaccaro A, Cirillo I, Tosca M, Massolo A, Passalacqua G. Nasal eosinophils display the best correlation with symptoms, pulmonary function and inflammation in allergic rhinitis. Int Arch Allergy Immunol. 2005; 136:266—72.

[170] Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol. 2003; 112:1021—31.

[171] Chen Y, Yang M, Deng J, Wang K, Shi J, Sun Y. Elevated Levels of Activated and Pathogenic Eosinophils Characterize Moderate—Severe House Dust Mite Allergic Rhinitis. J Immunol Res. 2020; 2020:8085615.

[172] Ahlstrom—Emanuelsson CA, Greiff L, Andersson M, Persson CGA, Erjefält JS . Eosinophil degranulation status in allergic rhinitis: observations before and during seasonal allergen exposure. Eur Respir J. 2004; 24:750-7.

[173] Xu X, Li J, Zhang X, Xi L, Gao Y, Li X, et al. Blood and local eosinophil levels in chronic rhinitis: Observations during seasonal allergen exposure and non—exposure. World Allergy Organ J. 2024; 17:100930.

[174] Melone G, Giorgis V, Di Pino M, Pelaia C, Nappi E, Heffler E, et al. Local Allergic Rhinitis: Lights and Shadows of a Mysterious Entity. Int Arch Allergy Immunol. 2023; 184:12-20.

[175] Campo P, Canonica GW. Local Allergic Rhinitis. J Allergy Clin Immunol Pract. 2024; 12:1430—3.

[176] Rondón C, Canto G, Blanca M. Local allergic rhinitis: a new entity, characterization and further studies. Curr Opin Allergy Clin Immunol. 2010; 10:1-7.

[177] Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome. Curr Allergy Asthma Rep. 2006; 6:215—20.

[178] Marra AM, Rossi CM, Piga MA, Moroncini G, Bilò MB. Eosinophil—associated diseases: the Allergist’s and Clinical Immunologist’s perspective. Eur Ann Allergy Clin Immunol. 2024; 56:195-209.

[179] Chua AJ, Jafar A, Luong AU. Update on allergic fungal rhinosinusitis. Ann Allergy Asthma Immunol. 2023; 131:300-6.

[180] Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021; 11:213-739.

[181] Wise SK, Damask C, Roland LT, Ebert C, Levy JM, Lin S, et al. International consensus statement on allergy and rhinology: Allergic rhinitis—2023. Int Forum Allergy Rhinol. 2023; 13:293-859.

[182] Di Lorenzo G, Pacor ML, Amodio E, Leto—Barone MS, La Piana S, D’Alcamo A, et al. Differences and similarities between allergic and nonallergic rhinitis in a large sample of adult patients with rhinitis symptoms. Int Arch Allergy Immunol. 2011; 155:263-70.

[183] Ciofalo A, Cavaliere C, Incorvaia C, Plath M, Ridolo E, Pucciarini F, et al. Diagnostic performance of nasal cytology. Eur Arch Otorhinolaryngol. 2022; 279:2451—5.

[184] Lam M, Hull L, McLachlan R, Snidvongs K, Chin D, Pratt E, et al. Clinical severity and epithelial endotypes in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013; 3:121—8.

[185] Snidvongs K, Lam M, Sacks R, Earls P, Kalish L, Phillips PS, et al. Structured histopathology profiling of chronic rhinosinusitis in routine practice. Int Forum Allergy Rhinol. 2012; 2:376-85.

[186] Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015; 70:995-1003.

[187] Grayson JW, Cavada M, Harvey RJ. Correction to: Clinically relevant phenotypes in chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2019; 48:31.

[188] Grayson JW, Hopkins C, Mori E, Senior B, Harvey RJ. Contemporary Classification of Chronic Rhinosinusitis Beyond Polyps vs No Polyps: A Review. JAMA Otolaryngol Head Neck Surg. 2020; 146:831—8.

[189] Rubel KE, Lubner RJ, Lopez AA, Li P, Huang LC, Sheng Q, et al. Inflammatory characteristics of central compartment atopic disease. Int Forum Allergy Rhinol. 2023; 13:2133—43.

[190] Ho J, Hamizan AW, Alvarado R, Rimmer J, Sewell WA, Harvey RJ. Systemic Predictors of Eosinophilic Chronic Rhinosinusitis. Am J Rhinol Allergy. 2018; 32:252-7.

[191] Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019; 74:2312—9.

[192] Aslan F, Altun E, Paksoy S, Turan G. Could Eosinophilia predict clinical severity in nasal polyps? Multidiscip Respir Med. 2017; 12:21.

[193] Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, et al. Presence of IL—5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010; 126:962-8.

[194] Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001; 107:607—14.

[195] Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin—exacerbated respiratory disease. Am J Rhinol Allergy. 2014; 28:287—9.

[196] Jonstam K, Westman M, Holtappels G, Holweg CTJ, Bachert C. Serum periostin, IgE, and SE—IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017; 140:1705—8.

[197] Kalpaklioglu AF, Kavut AB. Allergic and nonallergic rhinitis: can we find the differences/similarities between the two pictures? J Asthma. 2009; 46:481-5.

[198] Lee KS, Yu J, Shim D, Choi H, Jang MY, Kim KR, et al. Local Immune Responses in Children and Adults with Allergic and Nonallergic Rhinitis. PLoS One. 2016; 11:e0156979.

[199] Jung YG, Kim KH, Kim HY, Dhong HJ, Chung SK. Predictive capabilities of serum eosinophil cationic protein, percentage of eosinophils and total immunoglobulin E in allergic rhinitis without bronchial asthma. J Int Med Res. 2011; 39:2209—16.

[200] Demirjian M, Rumbyrt JS, Gowda VC, Klaustermeyer WB. Serum IgE and eosinophil count in allergic rhinitis—analysis using a modified Bayes’ theorem. Allergol Immunopathol (Madr). 2012; 40:281-7.

[201] Salo PM, Calatroni A, Gergen PJ, Hoppin JA, Sever ML, Jaramillo R, et al. Allergy—related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005—2006. J Allergy Clin Immunol. 2011; 127:1226-35.

[202] Liu W, Xia W, Fan Y, Wang H, Zuo K, Lai Y, et al. Elevated serum osteopontin level is associated with blood eosinophilia and asthma comorbidity in patients with allergic rhinitis. J Allergy Clin Immunol. 2012; 130:1416—8.

[203] Liu W, Zeng Q, Luo R. Correlation between Serum Osteopontin and miR—181a Levels in Allergic Rhinitis Children. Mediators Inflamm. 2016; 2016:9471215.

[204] Danielides G, Lygeros S, Kanakis M, Naxakis S. Periostin as a biomarker in chronic rhinosinusitis: A contemporary systematic review. Int Forum Allergy Rhinol. 2022; 12:1535—50.

[205] Sato T, Ikeda H, Murakami K, Murakami K, Shirane S, Ohta N. Periostin is an aggravating factor and predictive biomarker of eosinophilic chronic rhinosinusitis. Allergol Int. 2023; 72:161-8.

[206] Zhu XJ, Lu MP, Chen RX, Mao ZF, Yang YF, Han J, et al. Serum Periostin as a Potential Biomarker in the Evaluation of Allergic Rhinitis: A Pilot Study. J Asthma Allergy. 2025; 18:1-12.

[207] De Schryver E, Devuyst L, Derycke L, Dullaers M, Van Zele T, Bachert C, et al. Local immunoglobulin e in the nasal mucosa: clinical implications. Allergy Asthma Immunol Res. 2015; 7:321—31.

[208] Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, et al. Interleukin—5 in the Pathophysiology of Severe Asthma. Front Physiol. 2019; 10:1514.

[209] Liu P, Liu M, Sun Y, Yu M, Lei W, Xu Y. Osteopontin as a Novel Biomarker in Distinguishing Chronic Rhinosinusitis with Nasal Polyp Endotypes and Predicting Disease Severity. Int Arch Allergy Immunol. 2025; 186:473—83.

[210] Larenas—Linnemann DES, Loy LC, Abdullah B, Scadding GK. Moving Towards an Integrated Approach to Allergic Rhinitis Management: ARIA and EUFOREA Guidelines Similarities and Differences. Curr Allergy Asthma Rep. 2025; 25:30.

[211] Sousa—Pinto B, Vieira RJ, Bognanni A, Gil—Mata S, Ferreira—da—Silva R, Ferreira A, et al. Efficacy and safety of intranasal medications for allergic rhinitis: Network meta—analysis. Allergy. 2025; 80:94-105.

[212] Goto T, Miwa T, Hashimoto K, Amesara K, Unno Y, Sakamoto H. Evaluating the Efficacy of Omalizumab in Severe Cedar Seasonal Allergic Rhinitis in Japan. Cureus. 2024; 16:e63714.

[213] Hirano K, Suzaki I, Okuzawa N, Oki A, Otani Y, Takeuchi M, et al. Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation. Rhinology. 2025; 63:116—7.

[214] Müller M, Igarashi A, Hashiguchi K, Kappel M, Paolini F, Yoshisue H, et al. The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients. J Med Econ. 2022; 25:220—9.

[215] Zhang M, Ao T, Cheng L. Highlights of the treatment of allergic rhinitis according to Chinese guidelines. Curr Opin Allergy Clin Immunol. 2023; 23:334-40.

[216] Luk HG, Janz TA, Siddiqui FN, Hardison SA. Considerations for the Use of Biologics in Chronic Rhinosinusitis With Nasal Polyps. Ear Nose Throat J. 2025;1455613251363018.

[217] Zhong Y, Wei X, Zou C, Qian B, Ji H, Guo J, et al. Trends and future directions in chronic rhinosinusitis with nasal polyps: A bibliometric analysis. Braz J Otorhinolaryngol. 2025; 91:101672.

[218] Book R, Lazutkin A, Eliashar R . Long—Term Real—World Outcomes and Insights of Biologic Therapies in Chronic Rhinosinusitis with Nasal Polyps. Int J Mol Sci. 2025; 26:4694.

[219] Cai S, Xu S, Zhao Y, Zhang L. Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta—Analysis of Real—World Evidence. Allergy. 2025; 80:1256-70.

[220] Wang H, Xu X, Lu Z, Zhai Z, Shao L, Song X, et al. Efficacy of different biologics for treating chronic rhinosinusitis with nasal polyps: a network meta—analysis. Eur Arch Otorhinolaryngol. 2025; 282:559-69.

[221] Chhiba KD, Patel GB, Peters AT. Anti—IgE therapy in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2025; 155:24-30.

[222] Marco G, Arianna S, Domenico C, Gabriele O, Silvia LM, Giulia Z, et al. Efficacy of Dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric real—life study. Eur Arch Otorhinolaryngol. 2025; 282:4097-107.

[223] Kratchmarov R, Dharia T, Buchheit K. Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2025; 155:1401—10.

[224] Boechat JL, Silva D, Sousa—Pinto B, Delgado L. Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta—analysis. Allergy. 2022; 77:1299-306.

[225] Rodriguez—Iglesias M, Calvo—Henríquez C, Martin—Jimenez D, García—Lliberós A, Maza—Solano J, Moreno—Luna R, et al. Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta—analysis. Curr Allergy Asthma Rep. 2025; 25:13.

[226] Lipworth BJ, Greig R, Chan R, Kuo CR. Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps. J Allergy Clin Immunol Pract. 2025; 13:1943—51.

[227] Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first—ever presented phase 4 head—to—head respiratory study 2025 [Internet]. Sanofi; c2004—2026 [cited 2026 Jan 14]. Available from: https://www.sanofi.com/en/media—room/press—releases/2025/2025—06—15—15—22—00—3099494

[228] Lombardi C, Canevari RF, Bagnasco D, Bilò MB, Canonica GW, Caruso C, et al. ARIA—Italy multidisciplinary consensus on nasal polyposis and biological treatments: Update 2025. World Allergy Organ J. 2025; 18:101058.

[229] Buchheit KM, Vandewalle E, Elzinga HBE, Reitsma S, Fokkens W, Geveart P. Efficacy of Biologics in NSAID—ERD: United Airways From the Nose to the Bronchi. J Allergy Clin Immunol Pract. 2024; 12:2917-32.

[230] Ozdemir I, Bayar Muluk N, Yazır M, Cingi C. How does asthma coexistence affect the strategic selection of biologic therapies in CRSwNP management? Front Allergy. 2025; 6:1579224.

[231] Oka A, Klingler AI, Kidoguchi M, Poposki JA, Suh LA, Bai J, et al. Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis. J Allergy Clin Immunol. 2025; 156:463-7.

[232] Lipworth BJ, Han JK, Desrosiers M, Hopkins C, Lee SE, Mullol J, et al. ; WAYPOINT Study Investigators. Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2025; 392:1178—88.

[233] Kai Y. Tezepelumab treatment in severe asthma with recurrent chronic rhinosinusitis with nasal polyps: Case series. J Allergy Clin Immunol Glob. 2024; 4:100396.

[234] Nappi E, Paoletti G, Malvezzi L, Ferri S, Racca F, Messina MR, et al. Comorbid allergic rhinitis and asthma: important clinical considerations. Expert Rev Clin Immunol. 2022; 18:747-58.

[235] , editors. Biology of Eosinophils. In: Burks AW, O’Hehir RE, Broide DH, Holgate ST, Bacharier LB, Khurana Hershey GK, et al., editors. In: Middleton’s Allergy: Principles and Practice. 9th ed. New York: Elsevier; 2020.

[236] , editors. Asthma Pathogenesis. In: Burks AW, O’Hehir RE, Broide DH, Holgate ST, Bacharier LB, Khurana Hershey GK, et al., editors. In: Middleton’s Allergy: Principles and Practice. 9th ed. New York: Elsevier; 2020.

[237] Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008; 38:872-97.

[238] Hussain M, Liu G. Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons. Cells. 2024; 13:384.

[239] 2025 Global Strategy Report for Asthma Management and Prevention [Internet]. Global Initiative for Asthma—GINA; [cited 2026 Jan 12]. Available from: https://ginasthma.org/2025—gina—strategy—report/

[240] Nelson RK, Bush A, Stokes J, Nair P, Akuthota P. Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2020; 8:465-73.

[241] Heaney LG, Perez de Llano L, Al—Ahmad M, Backer V, Busby J, Canonica GW, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real—Life Severe Asthma Cohort. Chest. 2021; 160:814-30.

[242] Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol. 2015; 135:822—4.

[243] Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013; 19:977-9.

[244] Louis R, Sele J, Henket M, Cataldo D, Bettiol J, Seiden L, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid—naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy. 2002; 57:907-12.

[245] Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R . The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000; 161:9-16.

[246] Grunwell JR, Fitzpatrick AM. Asthma Phenotypes and Biomarkers. Respir Care. 2025; 70:649-74.

[247] Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. ; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011; 184:602—15.

[248] Brussino L, Heffler E, Bucca C, Nicola S, Rolla G. Eosinophils Target Therapy for Severe Asthma: Critical Points. Biomed Res Int. 2018; 2018:7582057.

[249] Rutten B, Young S, Rhedin M, Olsson M, Kurian N, Syed F, et al. Eosinophil—derived neurotoxin: A biologically and analytically attractive asthma biomarker. PLoS One. 2021; 16:e0246627.

[250] Kang YR, Kim H, Lee CE, Jung JW, Moon JY, Park SY, et al. Serum and urine eosinophil—derived neurotoxin (EDN) levels predict biologic response in severe asthma. World Allergy Organ J. 2025; 18:100990.

[251] West EE, Kashyap M, Leonard WJ. TSLP: A Key Regulator of Asthma Pathogenesis. Drug Discov Today Dis Mech. 2012; 9: 10.1016/j.ddmec.2012.09.003.

[252] Parnes JR, Molfino NA, Colice G, Martin U, Corren J, Menzies—Gow A. Targeting TSLP in Asthma. J Asthma Allergy. 2022; 15:749-65.

[253] Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017; 140:1509-18.

[254] Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010; 126:39-44.

[255] Lommatzsch M, Buhl R, Bergmann KC, Brusselle GG, Canonica GW, Jackson DJ, et al. Eosinophils in asthma phenotypes: perpetrators or guilty by association? Lancet Respir Med. 2025; 13:943—50.

[256] Özyiğit LP, Öztürk AB, Bavbek S. Anti—IL—5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turk Thorac J. 2020; 21:61-8.

[257] Niemiec—Górska A, Branicka O, Olszewska P, Mielcarska S, Glück J, Rymarczyk B, et al. The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma. Adv Respir Med. 2025; 93:21.

[258] Reza MI, Ambhore NS. Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic Frontiers. Biomedicines. 2025; 13:1342.

[259] Musburger BG, Gonzalez Echeandia M, Suskind EL, Suskind DL, Zheng HB, Mark D. Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review. Pharmaceutics. 2025; 17:753.

[260] Khoury P, Roufosse F, Kuang FL, Ackerman SJ, Akuthota P, Bochner BS, et al. ; International Eosinophil Society Clinical Research Interest Group. Biologic therapy in rare eosinophil—associated disorders: remaining questions and translational research opportunities. J Leukoc Biol. 2024; 116:307-20.

[261] Li W, Tang SC, Jin L. Adverse events of anti—IL—5 drugs in patients with eosinophilic asthma: a meta—analysis of randomized controlled trials and real—world evidence—based assessments. BMC Pulm Med. 2024; 24:70.

[262] Mobayed H, Al—Nesf M, Ibrahim T, Aqel S, Al—Ahmad M, Bousquet J. Secondary Non—Response to Biologic Treatment in Patients with Severe Asthma. J Asthma Allergy. 2025; 18:795-800.

[263] Kroes JA, Van Hal LHG, Van Dijk L, Zielhuis SW, Van Der Meer AN, Van Roon EN, et al. The perceived waning of biologics in severe asthma. Respir Med. 2023; 219:107416.

[264] Guida G, Bagnasco D, Carriero V, Bertolini F, Ricciardolo FLM, Nicola S, et al. Critical evaluation of asthma biomarkers in clinical practice. Front Med (Lausanne). 2022; 9:969243.

[265] Faria N, Costa MI, Fernandes AL, Fernandes A, Fernandes B, Machado DC, et al. Biologic Therapies for Severe Asthma: Current Insights and Future Directions. J Clin Med. 2025; 14:3153.

[266] David B, Bafadhel M, Koenderman L, De Soyza A . Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021; 76:188-95.

[267] Maniscalco M, Candia C, Ambrosino P, Iovine A, Fuschillo S. Chronic obstructive pulmonary disease’s eosinophilic phenotype: Clinical characteristics, biomarkers and biotherapy. Eur J Intern Med. 2025; 131:27-35.

[268] Kim VL, Coombs NA, Staples KJ, Ostridge KK, Williams NP, Wootton SA, et al. ; AERIS Study Group. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017; 50:1700853.

[269] Annangi S, Nutalapati S, Sturgill J, Flenaugh E, Foreman M. Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease. Thorax. 2022; 77:351—6.

[270] Singh D, Agusti A, Martinez FJ, Papi A, Pavord ID, Wedzicha JA, et al. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med. 2022; 206:17-24.

[271] Postma DS, Rabe KF. The Asthma—COPD Overlap Syndrome. N Engl J Med. 2015; 373:1241-9.

[272] Fricker M, McDonald VM, Winter NA, Baines KJ, Wark PAB, Simpson JL, et al. Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease. Allergy. 2021; 76:2079-89.

[273] Wu HX, Zhuo KQ, Cheng DY. Prevalence and Baseline Clinical Characteristics of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta—Analysis and Systematic Review. Front Med (Lausanne). 2019; 6:282.

[274] Jogdand P, Siddhuraj P, Mori M, Sanden C, Jönsson J, Walls AF, et al. Eosinophils, basophils and type 2 immune microenvironments in COPD—affected lung tissue. Eur Respir J. 2020; 55:1900110.

[275] Nejman—Gryz P, Górska K, Paplińska—Goryca M, Proboszcz M, Krenke R. Periostin and Thymic Stromal Lymphopoietin—Potential Crosstalk in Obstructive Airway Diseases. J Clin Med. 2020; 9:3667.

[276] Canè L, Poto R, Palestra F, Pirozzi M, Parashuraman S, Iacobucci I, et al. TSLP is localized in and released from human lung macrophages activated by T2—high and T2—low stimuli: relevance in asthma and COPD. Eur J Intern Med. 2024; 124:89-98.

[277] Saber Cherif L, Devilliers MA, Perotin JM, Ancel J, Vivien A, Bonnomet A, et al. TSLP and TSLPr Expression and Localization in the Airways of COPD and Non—COPD Patients. Eur J Immunol. 2025; 55:e202451480.

[278] Chou KT, Su KC, Hsiao YH, Huang SF, Ko HK, Tseng CM, et al. Post—bronchodilator Reversibility of FEV₁ and Eosinophilic Airway Inflammation in COPD . Arch Bronconeumol. 2017; 53:547-53. Spanish.

[279] Leung C, Park HY, Li X, Koelwyn GJ, Tuong J, Vahedi SM, et al. Transcriptomic profiling of the airway epithelium in COPD links airway eosinophilia to type 2 inflammation and corticosteroid response. Eur Respir J. 2025; 65:2401875.

[280] Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez—Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post—hoc analysis of the WISDOM trial. Lancet Respir Med. 2016; 4:390-8.

[281] Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. ; COPDGene and ECLIPSE Investigators. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018; 141:2037—47.

[282] Brightling CE, Ward R, Goh KL, Wardlaw AJ, Pavord ID. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med. 1999; 160:406—10.

[283] Gonlugur U, Gonlugur TE. Eosinophilic bronchitis without asthma. Int Arch Allergy Immunol. 2008; 147:1-5.

[284] Cho J, Choi SM, Lee J, Park YS, Lee SM, Yoo CG, et al. Clinical Outcome of Eosinophilic Airway Inflammation in Chronic Airway Diseases Including Nonasthmatic Eosinophilic Bronchitis. Sci Rep. 2018; 8:146.

[285] Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma. Eur Respir J. 1999; 14:1228—30.

[286] Matera MG, Calzetta L, Cazzola M, Ora J, Rogliani P. Biologic therapies for chronic obstructive pulmonary disease. Expert Opin Biol Ther. 2023; 23:163-73.

[287] Mohamed MMG, Kamel G, Charbek E. Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta—analysis of Randomized Controlled Trials. Ann Am Thorac Soc. 2025; 22:768—75.

[288] Hu KC, Chuang MH, Lai CC, Liao KM. Meta—Analysis of Randomized, Controlled Trials Assessing the Effectiveness and Safety of Biological Treatments in Chronic Obstructive Pulmonary Disease Patients. Clin Ther. 2025; 47:226-34.

[289] Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. ; BOREAS Investigators. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023; 389:205-14.

[290] Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. ; NOTUS Study Investigators. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024; 390:2274—83.

[291] Brightling CE. Cough due to asthma and nonasthmatic eosinophilic bronchitis. Lung. 2010; 188 Suppl 1:S13-7.

[292] Brightling CE. Eosinophils, bronchitis and asthma: pathogenesis of cough and airflow obstruction. Pulm Pharmacol Ther. 2011; 24:324-7.

[293] Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022; 386:157-71.

[294] Asano K, Suzuki Y, Tanaka J, Kobayashi K, Kamide Y. Treatments of refractory eosinophilic lung diseases with biologics. Allergol Int. 2023; 72:31-40.

[295] Olivieri B, Tinazzi E, Caminati M, Lunardi C. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders. Immunol Allergy Clin North Am. 2020; 40:649-65.

[296] Tamada T, Ichinose M. Leukotriene Receptor Antagonists and Antiallergy Drugs. Handb Exp Pharmacol. 2017; 237:153-69.

[297] Jayaram L, Duong M, Pizzichini MMM, Pizzichini E, Kamada D, Efthimiadis A, et al. Failure of montelukast to reduce sputum eosinophilia in high—dose corticosteroid—dependent asthma. Eur Respir J. 2005; 25:41-6.

[298] Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. ; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022; 81:309—14.

[299] Vega Villanueva KL, Espinoza LR. Eosinophilic Vasculitis. Curr Rheumatol Rep. 2020; 22:5.

[300] Wu EY, Hernandez ML, Jennette JC, Falk RJ. Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review. J Allergy Clin Immunol Pract. 2018; 6:1496-504.

[301] Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg—Strauss): state of the art. Allergy. 2013; 68:261-73.

[302] Boita M, Guida G, Circosta P, Elia AR, Stella S, Heffler E, et al. The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA). Clin Immunol. 2014; 152:152-63.

[303] Trivioli G, Marquez A, Martorana D, Tesi M, Kronbichler A, Lyons PA, et al. Genetics of ANCA—associated vasculitis: role in pathogenesis, classification and management. Nat Rev Rheumatol. 2022; 18:559-74.

[304] Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, et al. Evidence—Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023; 19:378-93.

[305] Hellmich B, Sanchez—Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA—associated vasculitis: 2022 update. Ann Rheum Dis. 2024; 83:30-47.

[306] Agarwal R, Muthu V, Sehgal IS. Clinical Manifestation and Treatment of Allergic Bronchopulmonary Aspergillosis. Semin Respir Crit Care Med. 2024; 45:114-27.

[307] Caminati M, Annesi—Maesano I, Feleszko W, Guida G, Janson C, Hägg S, et al. Fungal—Driven Airways Dis—Immunity From Asthma to Allergic Bronchopulmonary Aspergillosis: Dissecting Similarities and Differences. An EAACI Task Force Report. Allergy. 2025; 80:3274-89.

[308] Ueki S, Hebisawa A, Kitani M, Asano K, Neves JS. Allergic Bronchopulmonary Aspergillosis—A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death. Front Immunol. 2018; 9:2346.

[309] Greenberger PA, Bush RK, Demain JG, Luong A, Slavin RG, Knutsen AP. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2014; 2:703—8.

[310] Saxena P, Choudhary H, Muthu V, Sehgal IS, Dhooria S, Prasad KT, et al. Which Are the Optimal Criteria for the Diagnosis of Allergic Bronchopulmonary Aspergillosis? A Latent Class Analysis. J Allergy Clin Immunol Pract. 2021; 9:328-35.

[311] Asano K, Hebisawa A, Ishiguro T, Takayanagi N, Nakamura Y, Suzuki J, et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 2021; 147:1261—8.

[312] Agarwal R, Muthu V, Sehgal IS, Dhooria S, Prasad KT, Aggarwal AN. Allergic Bronchopulmonary Aspergillosis. Clin Chest Med. 2022; 43:99-125.

[313] Eraso IC, Sangiovanni S, Morales EI, Fernández—Trujillo L. Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review. Ther Adv Respir Dis. 2020; 14:1753466620961648.

[314] De Giacomi F, Decker PA, Vassallo R, Ryu JH. Acute Eosinophilic Pneumonia: Correlation of Clinical Characteristics With Underlying Cause. Chest. 2017; 152:379-85.

[315] Allen JN, Pacht ER, Gadek JE, Davis WB . Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med. 1989; 321:569-74.

[316] Rom WN, Weiden M, Garcia R, Yie TA, Vathesatogkit P, Tse DB, et al. Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. Am J Respir Crit Care Med. 2002; 166:797-800.

[317] Shorr AF, Scoville SL, Cersovsky SB, Shanks GD, Ockenhouse CF, Smoak BL, et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA. 2004; 292:2997-3005.

[318] Bonnier A, Saha S, Shkolnik B, Saha BK. A comparative analysis of acute eosinophilic pneumonia associated with smoking and vaping. Am J Med Sci. 2023; 365:315—7.

[319] Christiani DC. Vaping—Induced Acute Lung Injury. N Engl J Med. 2020; 382:960-2.

[320] Cottin V, Cordier JF. Eosinophilic Pneumonia. In: Cottin V, Cordier JF, Richeldi L, editors. Orphan Lung Diseases: A Clinical Guide to Rare Lung Disease. London: Springer; 2015. pp. 227—51.

[321] Philit F, Etienne—Mastroïanni B, Parrot A, Guérin C, Robert D, Cordier JF. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med. 2002; 166:1235—9.

[322] Daimon T, Johkoh T, Sumikawa H, Honda O, Fujimoto K, Koga T, et al. Acute eosinophilic pneumonia: Thin—section CT findings in 29 patients. Eur J Radiol. 2008; 65:462—7.

[323] Umeki S, Soejima R. Acute and chronic eosinophilic pneumonia: clinical evaluation and the criteria. Intern Med. 1992; 31:847-56.

[324] Rhee CK, Min KH, Yim NY, Lee JE, Lee NR, Chung MP, et al. Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J. 2013; 41:402-9.

[325] Wechsler ME. Pulmonary eosinophilic syndromes. Immunol Allergy Clin North Am. 2007; 27:477-92.

[326] Marchand E, Reynaud—Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF. Idiopathic chronic eosinophilic pneumonia. A clinical and follow—up study of 62 cases. The Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore). 1998; 77:299-312.

[327] Okubo Y, Horie S, Hachiya T, Momose T, Tsukadaira A, Takashi S, et al. Predominant implication of IL—5 in acute eosinophilic pneumonia: comparison with chronic eosinophilic pneumonia. Int Arch Allergy Immunol. 1998; 116:76-80.

[328] Cottin V. Eosinophilic Lung Diseases. Clin Chest Med. 2016; 37:535-56.

[329] Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR Am J Roentgenol. 1977; 128:1-13.

[330] Marchand E, Cordier JF. Idiopathic chronic eosinophilic pneumonia. Semin Respir Crit Care Med. 2006; 27:134—41.

[331] Suzuki Y, Suda T. Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management. Allergol Int. 2019; 68:413—9.

[332] Kim SJ, Bista AB, Park KJ, Kang DK, Park JH, Park KJ, et al. Simple pulmonary eosinophilia found on follow—up computed tomography of oncologic patients. Eur J Radiol. 2014; 83:1977—82.

[333] Chung SY, Lee JH, Kim TH, Yun M, Kim TS, Kim SJ, et al. F—18 FDG PET scan findings in patients with Loeffler’s syndrome. Clin Nucl Med. 2009; 34:570—5.

[334] Uppal P, LaPlante KL, Gaitanis MM, Jankowich MD, Ward KE. Daptomycin—induced eosinophilic pneumonia—a systematic review. Antimicrob Resist Infect Control. 2016; 5:55.

[335] Bartal C, Sagy I, Barski L. Drug—induced eosinophilic pneumonia: A review of 196 case reports. Medicine (Baltimore). 2018; 97:e9688.

[336] Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol. 2018; 35:260-71.

[337] Erasmus JJ, McAdams HP, Rossi SE. Drug—induced lung injury. Semin Roentgenol. 2002; 37:72-81.

[338] Minozzi S, Bonovas S, Lytras T, Pecoraro V, González—Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti—TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta—analysis. Expert Opin Drug Saf. 2016; 15:11-34.

[339] Larsen BT, Vaszar LT, Colby TV, Tazelaar HD. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone—induced lung toxicity. Am J Surg Pathol. 2012; 36:509—16.

[340] Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024; 99:946-68.

[341] Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023; 78:47-59.

[342] Jackson DJ, Akuthota P, Roufosse F. Eosinophils and eosinophilic immune dysfunction in health and disease. Eur Respir Rev. 2022; 31:210150.

[343] Iurlo A, Cattaneo D. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management? Blood Rev. 2023; 58:101014.

[344] Nguyen L, Saha A, Kuykendall A, Zhang L. Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis. Cancers (Basel). 2024; 16:1383.

[345] Piccirillo F, Watanabe M, Di Sciascio G. Diagnosis, treatment and predictors of prognosis of myocarditis. A narrative review. Cardiovasc Pathol. 2021; 54:107362.

[346] Salihu A, Stadelmann R, Solimando E, Schwitter J. Eosinophilic myocarditis during treatment of acute myeloid leukaemia: cardiac magnetic resonance in the very early phase mimicking triple—vessel coronary artery disease: a case report. Eur Heart J Case Rep. 2023; 7:ytad185.

[347] Chaudhry MA, Grazette L, Yoon A, Correa A, Fong MW. Churg—Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature. Curr Hypertens Rev. 2019; 15:8-12.

[348] Lipof JJ, Huselton EJ, Zent CS, Evans A, Zhang B, Rothberg PG, et al. A Case of Acute Eosinophilic Leukemia with a Novel PHF6 Mutation . Case Rep Hematol. 2021; 2021:5574766.

[349] Cheng CY, Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP. Myocarditis in systemic immune—mediated diseases: Prevalence, characteristics and prognosis. A systematic review. Autoimmun Rev. 2022; 21:103037.

[350] Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med. 2011; 6:487-95.

[351] Bracamonte—Baran W, Čiháková D. Cardiac Autoimmunity: Myocarditis. Adv Exp Med Biol. 2017; 1003:187-221.

[352] Watanabe M, Panetta GL, Piccirillo F, Spoto S, Myers J, Serino FM, et al. Acute Epstein—Barr related myocarditis: An unusual but life—threatening disease in an immunocompetent patient. J Cardiol Cases. 2019; 21:137-40.

[353] Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. J Am Coll Cardiol. 2017; 70:2363—75.

[354] Sheikh H, Siddiqui M, Uddin SMM, Haq A, Yaqoob U. The Clinicopathological Profile of Eosinophilic Myocarditis. Cureus. 2018; 10:e3677.

[355] Amini R, Nielsen C. Eosinophilic myocarditis mimicking acute coronary syndrome secondary to idiopathic hypereosinophilic syndrome: a case report. J Med Case Rep. 2010; 4:40.

[356] Barin JG, Baldeviano GC, Talor MV, Wu L, Ong S, Fairweather D, et al. Fatal eosinophilic myocarditis develops in the absence of IFN—γ and IL—17A. J Immunol. 2013; 191:4038-47.

[357] Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, et al. ; Secondary and Primary Vasculitis Study Group. HLA—DRB4 as a genetic risk factor for Churg—Strauss syndrome. Arthritis Rheum. 2007; 56:3159-66.

[358] Wieczorek S, Hellmich B, Gross WL; Epplen JT. Associations of Churg—Strauss syndrome with the HLA—DRB1 locus; and relationship to the genetics of antineutrophil cytoplasmic antibody—associated vasculitides: comment on the article by Vaglio et al.. Associations of Churg—Strauss syndrome with the HLA—DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody—associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum. 2008; 58:329—30.

[359] Wojnicz R, Nowalany—Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, et al. Randomized, placebo—controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two—year follow—up results. Circulation. 2001; 104:39-45.

[360] Al Ali AM, Straatman LP, Allard MF, Ignaszewski AP. Eosinophilic myocarditis: case series and review of literature. Can J Cardiol. 2006; 22:1233—7.

[361] Takkenberg JJM, Czer LSC, Fishbein MC, Luthringer DJ, Quartel AW, Mirocha J, et al. Eosinophilic myocarditis in patients awaiting heart transplantation. Crit Care Med. 2004; 32:714—21.

[362] Russo M, Ismibayli Z, Antonaci S, Piccinni GC. Eosinophilic myocarditis: from etiology to diagnostics and therapy. Minerva Cardiol Angiol. 2024; 72:656-73.

[363] Park H, Park H, Lee D, Oh S, Lim J, Hwang HJ, et al. Increased phosphorylation of Ca(2+) handling proteins as a proarrhythmic mechanism in myocarditis. Circ J. 2014; 78:2292-301.

[364] Frustaci A, Chimenti C. Immunosuppressive therapy in myocarditis. Circ J. 2015; 79:4-7.

[365] Dec GW Jr, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med. 1985; 312:885-90.

[366] Miyagawa M, Yokoyama R, Nishiyama Y, Ogimoto A, Higaki J, Mochizuki T. Positron emission tomography—computed tomography for imaging of inflammatory cardiovascular diseases. Circ J. 2014; 78:1302—10.

[367] Kawai S, Shimada T. Inflammation in takotsubo cardiomyopathy? Inquiry from “Guidelines for Diagnosis and Treatment of Myocarditis (JCS 2009)”. J Cardiol. 2014; 63:247—9.

[368] Yamamoto H, Hashimoto K, Ikeda Y, Isogai J, Hashimoto T. The Diagnostic Challenge of Eosinophilic Granulomatosis With Polyangiitis Presenting as Acute Eosinophilic Myocarditis: Case Report and Literature Review. Front Cardiovasc Med. 2022; 9:913724.

[369] Noth I, Strek ME, Leff AR. Churg—Strauss syndrome. Lancet. 2003; 361:587-94.

[370] Pakbaz M, Pakbaz M. Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Meta—Analysis of 62 Case Reports. J Tehran Heart Cent. 2020; 15:18-26.

[371] Boussir H, Ghalem A, Ismaili N, El Ouafi N. Eosinophilic myocarditis and hypereosinophilic syndrome. J Saudi Heart Assoc. 2017; 29:211—3.

[372] Requena G, van den Bosch J, Akuthota P, Kovalszki A, Steinfeld J, Kwon N, et al. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. J Allergy Clin Immunol Pract. 2022; 10:2125—34.

[373] Piccirillo F, Mastroberardino S, Nafisio V, Fiorentino M, Segreti A, Nusca A, et al. Eosinophilic Myocarditis: From Bench to Bedside. Biomedicines. 2024; 12:656.

[374] Friedrich MG, Sechtem U, Schulz—Menger J, Holmvang G, Alakija P, Cooper LT, et al. ; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009; 53:1475-87.

[375] Zhong Z, Yang Z, Peng Y, Wang L, Yuan X. Diagnosis and treatment of eosinophilic myocarditis. J Transl Autoimmun. 2021; 4:100118.

[376] Markousis—Mavrogenis G, Sfikakis PP, Koutsogeorgopoulou L, Dimitroulas T, Katsifis G, Giannakopoulou A, et al. Cardiovascular Magnetic Resonance Reveals Cardiac Pathophysiology in Autoimmune Rheumatic Diseases. Mediterr J Rheumatol. 2021; 32:15-20.

[377] Liu X, Zhou Y, Li J, Guo T, Lv Z, Zhang D, et al. Cardiac involvement in eosinophilic granulomatosis with polyangiitis: acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy. Rheumatology (Oxford). 2025; 64:722—31.

[378] Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987; 4:3-14.

[379] Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. ; Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007; 50:1914—31.

[380] Kaneda T, Iwai S, Suematsu T, Yamamoto R, Takata M, Higashikata T, et al. Acute necrotizing eosinophilic myocarditis complicated by complete atrioventricular block promptly responded to glucocorticoid therapy. J Cardiol Cases. 2017; 16:5-8.

[381] Cottu A, Groh M, Desaintjean C, Marchand—Adam S, Guillevin L, Puechal X, et al. ; French Vasculitis Study Group. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2023; 82:1580-6.

[382] Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010; 122:900-9.

[383] Cheung CC, Constantine M, Ahmadi A, Shiau C, Chen LYC. Eosinophilic Myocarditis. Am J Med Sci. 2017; 354:486-92.

[384] Techasatian W, Gozun M, Vo K, Yokoyama J, Nagamine T, Shah P, et al. Eosinophilic myocarditis: systematic review. Heart. 2024; 110:687-93.

[385] Kuchynka P, Palecek T, Masek M, Cerny V, Lambert L, Vitkova I, et al. Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis. Biomed Res Int. 2016; 2016:2829583.

[386] Diny NL, Baldeviano GC, Talor MV, Barin JG, Ong S, Bedja D, et al. Eosinophil—derived IL—4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med. 2017; 214:943-57.

[387] Rosenberg CE, Khoury P. Approach to Eosinophilia Presenting With Pulmonary Symptoms. Chest. 2021; 159:507—16.

[388] Sergew A, Fernández Pérez ER . Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome. Semin Respir Crit Care Med. 2016; 37:441-56.

[389] Cottin V. Eosinophilic Lung Diseases. Immunol Allergy Clin North Am. 2023; 43:289-322.

[390] Altamura M, D’Andrea G, Angelini E, Tortorelli FMP, Balzotti A, Porcelli P, et al. Psychosomatic syndromes are associated with IL—6 pro—inflammatory cytokine in heart failure patients. PLoS One. 2022; 17:e0265282.

[391] Tylee DS, Lee YK, Wendt FR, Pathak GA, Levey DF, De Angelis F, et al. An Atlas of Genetic Correlations and Genetically Informed Associations Linking Psychiatric and Immune—Related Phenotypes. JAMA Psychiatry. 2022; 79:667-76.

[392] Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med. 2004; 351:940—1.

[393] Navarro P, Arias Á, Arias—González L, Laserna—Mendieta EJ, Ruiz—Ponce M, Lucendo AJ. Systematic review with meta—analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population—based studies. Aliment Pharmacol Ther. 2019; 49:1116-25.

[394] Biedermann L, Straumann A. Mechanisms and clinical management of eosinophilic oesophagitis: an overview. Nat Rev Gastroenterol Hepatol. 2023; 20:101-19.

[395] Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, et al. Coordinate interaction between IL—13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010; 184:4033-41.

[396] Dsilva A, Wagner A, Itan M, Rhone N, Avlas S, Gordon Y, et al. Distinct Roles for Thymic Stromal Lymphopoietin (TSLP) and IL—33 in Experimental Eosinophilic Esophagitis. Allergy. 2025; 80:3095-107.

[397] Sherrill JD, Kc K, Wu D, Djukic Z, Caldwell JM, Stucke EM, et al. Desmoglein—1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol. 2014; 7:718—29.

[398] Doyle AD, Masuda MY, Pyon GC, Luo H, Putikova A, LeSuer WE, et al. Detergent exposure induces epithelial barrier dysfunction and eosinophilic inflammation in the esophagus. Allergy. 2023; 78:192-201.

[399] Doyle AD, Masuda MY, Kita H, Wright BL. Eosinophils in Eosinophilic Esophagitis: The Road to Fibrostenosis is Paved With Good Intentions. Front Immunol. 2020; 11:603295.

[400] van de Veen W, Globinska A, Jansen K, Straumann A, Kubo T, Verschoor D, et al. A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. Sci Adv. 2020; 6:eaaz3559.

[401] Kleuskens MTA, Haasnoot ML, Garssen J, Bredenoord AJ, van Esch BCAM, Redegeld FA. Transcriptomic profiling of the acute mucosal response to local food injections in adults with eosinophilic esophagitis. J Allergy Clin Immunol. 2024; 153:780-92.

[402] Ding J, Garber JJ, Uchida A, Lefkovith A, Carter GT, Vimalathas P, et al. An esophagus cell atlas reveals dynamic rewiring during active eosinophilic esophagitis and remission. Nat Commun. 2024; 15:3344.

[403] Doshi A, Khamishon R, Rawson R, Duong L, Dohil L, Myers SJ, et al. Interleukin 9 Alters Epithelial Barrier and E—cadherin in Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2019; 68:225-31.

[404] Lozano—Ojalvo D, Chen X, Kazmi W, Menchén—Martínez D, Pérez—Rodríguez L, Fernandes—Braga W, et al. Differential T follicular helper cell phenotypes distinguish IgE—mediated milk allergy from eosinophilic esophagitis in children. J Allergy Clin Immunol. 2025; 155:909-22.

[405] Loizou D, Enav B, Komlodi—Pasztor E, Hider P, Kim—Chang J, Noonan L, et al. A pilot study of omalizumab in eosinophilic esophagitis. PLoS One. 2015; 10:e0113483.

[406] Nhu QM, Aceves SS. Current state of biologics in treating eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2023; 130:15-20.

[407] Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr. 2011; 170:1471—4.

[408] Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014; 147:602-9.

[409] Schuyler AJ, Wilson JM, Tripathi A, Commins SP, Ogbogu PU, Kruzsewski PG, et al. Specific IgG₄ antibodies to cow’s milk proteins in pediatric patients with eosinophilic esophagitis . J Allergy Clin Immunol. 2018; 142:139—48.

[410] Wright BL, Kulis M, Guo R, Orgel KA, Wolf WA, Burks AW, et al. Food—specific IgG₄ is associated with eosinophilic esophagitis . J Allergy Clin Immunol. 2016; 138:1190—2.

[411] Medernach JG, Li RC, Zhao XY, Yin B, Noonan EA, Etter EF, et al. Immunoglobulin G4 in eosinophilic esophagitis: Immune complex formation and correlation with disease activity. Allergy. 2023; 78:3193-203.

[412] Bel Imam B, Iwasaki S, Lems S, Cevhertas L, Westermann P, Larsen LB, et al. ; Swiss EoE Cohort Study Group. Circulating Food Allergen—Specific Antibodies, Beyond IgG4, Are Elevated in Eosinophilic Esophagitis. Clin Exp Allergy. 2025; 55:916-27.

[413] Kottyan LC, Parameswaran S, Weirauch MT, Rothenberg ME, Martin LJ. The genetic etiology of eosinophilic esophagitis. J Allergy Clin Immunol. 2020; 145:9-15.

[414] Sato H, Osonoi K, Sharlin CS, Shoda T. Genetic and Molecular Contributors in Eosinophilic Esophagitis. Curr Allergy Asthma Rep. 2023; 23:255-66.

[415] Miehlke S. Clinical features of Eosinophilic esophagitis in children and adults. Best Pract Res Clin Gastroenterol. 2015; 29:739—48.

[416] Kennedy KV, Umeweni CN, Alston M, Dolinsky L, McCormack SM, Taylor LA, et al. Esophageal Remodeling Correlates With Eating Behaviors in Pediatric Eosinophilic Esophagitis. Am J Gastroenterol. 2024; 119:1167—76.

[417] Dellon ES, Muir AB, Katzka DA, Shah SC, Sauer BG, Aceves SS, et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. Am J Gastroenterol. 2025; 120:31-59.

[418] Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, et al. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology. 2022; 163:59-76.

[419] Gueguen E, Morsy Y, Biedermann L, Straumann A; Swiss EoE Cohort Study Group; Scharl M, Wawrzyniak M. A Distinct Genetic Signature Differentiates Inflamed and Noninflamed Fibrotic Tissues in Eosinophilic Esophagitis Patients. Allergy. 2025; 80:2043—6.

[420] Gueguen E, Morsy Y, Mamie C, Schoepfer A, Saner C, Biedermann L, et al. Novel transcriptomic panel identifies histologically active eosinophilic oesophagitis. Gut. 2024; 73:1076-86.

[421] Wen T, Stucke EM, Grotjan TM, Kemme KA, Abonia JP, Putnam PE, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology. 2013; 145:1289—99.

[422] González de Béthencourt E, Greuter T . Eosinophilic Esophagitis without Eosinophils: Do You Want to Mock Me? Inflamm Intest Dis. 2025; 10:126-34.

[423] Greuter T, Straumann A, Fernandez—Marrero Y, Germic N, Hosseini A, Yousefi S, et al. Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross—sectional multi—center study. Allergy. 2022; 77:2520—33.

[424] Doerfler B, Lam AY, Gonsalves N. Dietary Management of Eosinophilic Esophagitis. Gastroenterol Hepatol (N Y). 2023; 19:680—90.

[425] Molina—Infante J, Arias Á, Alcedo J, Garcia—Romero R, Casabona—Frances S, Prieto—Garcia A, et al. Step—up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2—4—6 study. J Allergy Clin Immunol. 2018; 141:1365-72.

[426] Walgraeve S, Vanuytsel T. Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence? Acta Gastroenterol Belg. 2023; 86:437-48.

[427] Dougherty M, Runge TM, Eluri S, Dellon ES. Esophageal dilation with either bougie or balloon technique as a treatment for eosinophilic esophagitis: a systematic review and meta—analysis. Gastrointest Endosc. 2017; 86:581-91.

[428] Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013; 62:1395—405.

[429] Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, et al. Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two—Center Study. Am J Gastroenterol. 2017; 112:1538—44.

[430] Shoda T, Taylor RJ, Sakai N, Rothenberg ME. Common and disparate clinical presentations and mechanisms in different eosinophilic gastrointestinal diseases. J Allergy Clin Immunol. 2024; 153:1472-84.

[431] Dellon ES, Gonsalves N, Abonia JP, Alexander JA, Arva NC, Atkins D, et al. International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clin Gastroenterol Hepatol. 2022; 20:2474-84.

[432] Chehade M, Jones SM, Pesek RD, Burks AW, Vickery BP, Wood RA, et al. Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research. J Allergy Clin Immunol Pract. 2018; 6:1534—44.

[433] Ben—Tov A, Melzer—Cohen C, Yahalom R, Yarden A, Livnat I, Patalon T, et al. Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade. J Gastroenterol Hepatol. 2025; 40:413-20.

[434] Li K, Ruan G, Liu S, Xu T, Guan K, Li J, et al. Eosinophilic gastroenteritis: Pathogenesis, diagnosis, and treatment. Chin Med J (Engl). 2023; 136:899-909.

[435] Abou Rached A, El Hajj W . Eosinophilic gastroenteritis: Approach to diagnosis and management. World J Gastrointest Pharmacol Ther. 2016; 7:513-23.

[436] Caldwell JM, Collins MH, Stucke EM, Putnam PE, Franciosi JP, Kushner JP, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol. 2014; 134:1114—24.

[437] Shoda T, Matsuda A, Arai K, Shimizu H, Morita H, Orihara K, et al. Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL—33 levels. J Allergy Clin Immunol. 2016; 138:299-303.

[438] Shoda T, Wen T, Caldwell JM, Collins MH, Besse JA, Osswald GA, et al. Molecular, endoscopic, histologic, and circulating biomarker—based diagnosis of eosinophilic gastritis: Multi—site study. J Allergy Clin Immunol. 2020; 145:255-69.

[439] Shoda T, Collins MH, Rochman M, Wen T, Caldwell JM, Mack LE, et al. Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi—Site Study. Gastroenterology. 2022; 162:1635—49.

[440] Shoda T, Rochman M, Collins MH, Caldwell JM, Mack LE, Osswald GA, et al. Molecular analysis of duodenal eosinophilia. J Allergy Clin Immunol. 2023; 151:1027—39.

[441] Papadopoulou A, Amil—Dias J, Auth MK, Chehade M, Collins MH, Gupta SK, et al. Joint ESPGHAN/NASPGHAN Guidelines on Childhood Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2024; 78:122-52.

[442] Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database. J Pediatr Gastroenterol Nutr. 2016; 62:36-42.

[443] Hirano I, Collins MH, King E, Sun Q, Chehade M, Abonia JP, et al. Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort. Am J Gastroenterol. 2022; 117:413—23.

[444] Di Gioacchino M, Pizzicannella G, Fini N, Falasca F, Antinucci R, Masci S, et al. Sodium cromoglicate in the treatment of Eosinophilic Gastroenteritis. Allergy. 1990; 45:161—6.

[445] Pesek RD, Reed CC, Collins MH, Muir AB, Fulkerson PC, Menard—Katcher C, et al. Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non—esophageal Eosinophilic Gastrointestinal Disorders. Dig Dis Sci. 2020; 65:2024-35.

[446] Chen X, Ding X, Ko HM. Non—esophageal eosinophilic gastrointestinal disorders. Hum Pathol Rep. 2022; 29:300655.

[447] Low EE, Dellon ES. Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases. Aliment Pharmacol Ther. 2024; 59:322-40.

[448] Chang JY, Choung RS, Lee RM, Locke GR 3rd, Schleck CD, Zinsmeister AR, et al. A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type. Clin Gastroenterol Hepatol. 2010; 8:669-75: quiz e88.

[449] Kinoshita Y, Furuta K, Ishimaura N, Ishihara S, Sato S, Maruyama R, et al. Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis. J Gastroenterol. 2013; 48:333—9.

[450] Tan AC, Kruimel JW, Naber TH. Eosinophilic gastroenteritis treated with non—enteric—coated budesonide tablets. Eur J Gastroenterol Hepatol. 2001; 13:425-7.

[451] Kliewer KL, Murray—Petzold C, Collins MH, Abonia JP, Bolton SM, DiTommaso LA, et al. Benralizumab for eosinophilic gastritis: a single—site, randomised, double—blind, placebo—controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2023; 8:803—15.

[452] Dellon ES, Peterson KA, Murray JA, Falk GW, Gonsalves N, Chehade M, et al. Anti—Siglec—8 Antibody for Eosinophilic Gastritis and Duodenitis. N Engl J Med. 2020; 383:1624—34.

[453] Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases [Internet]. Allakos; [cited 2026 Jan 25]. Available from: https://www.globenewswire.com/news—release/2021/12/22/2356444/0/en/Allakos—Announces—Topline—Phase—3—Data—from—the—ENIGMA—2—Study—and—Phase—2—3—Data—from—the—KRYPTOS—Study—in—Patients—with—Eosinophilic—Gastrointestinal—Diseases.html

[454] Gazzinelli—Guimaraes PH, de Queiroz Prado R, Ricciardi A, Bonne—Année S, Sciurba J, Karmele EP, et al. Allergen presensitization drives an eosinophil—dependent arrest in lung—specific helminth development. J Clin Invest. 2019; 129:3686-701.

[455] Ovington KS, Behm CA. The enigmatic eosinophil: investigation of the biological role of eosinophils in parasitic helminth infection. Mem Inst Oswaldo Cruz. 1997; 92 Suppl 2:93-104.

[456] Shin MH, Lee YA, Min DY. Eosinophil—mediated tissue inflammatory responses in helminth infection. Korean J Parasitol. 2009; 47 Suppl:S125-31.

[457] David JR, Vadas MA, Butterworth AE, de Brito PA, Carvalho EM, David RA, et al. Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia. N Engl J Med. 1980; 303:1147—52.

[458] Kantor O Jr, Rosário Filho NA. Hypodense eosinophils in blood of pediatric patients with asthma. J Pediatr (Rio J). 1997; 73:16-20. Portuguese.

[459] Roan F, Obata—Ninomiya K, Ziegler SF. Epithelial cell—derived cytokines: more than just signaling the alarm. J Clin Invest. 2019; 129:1441-51.

[460] Stanbery AG, Smita S, von Moltke J, Tait Wojno ED, Ziegler SF. TSLP, IL—33, and IL—25: Not just for allergy and helminth infection. J Allergy Clin Immunol. 2022; 150:1302-13.

[461] Liew FY, Girard JP, Turnquist HR. Interleukin—33 in health and disease. Nat Rev Immunol. 2016; 16:676-89.

[462] Rodrigo—Muñoz JM, Gil—Martínez M, Sastre B, Del Pozo V . Emerging Evidence for Pleiotropism of Eosinophils. Int J Mol Sci. 2021; 22:7075.

[463] Jacobsen EA, Lesuer WE, Willetts L, Zellner KR, Mazzolini K, Antonios N, et al. Eosinophil activities modulate the immune/inflammatory character of allergic respiratory responses in mice. Allergy. 2014; 69:315—27.

[464] Specht S, Saeftel M, Arndt M, Endl E, Dubben B, Lee NA, et al. Lack of eosinophil peroxidase or major basic protein impairs defense against murine filarial infection. Infect Immun. 2006; 74:5236—43.

[465] Persson EK, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier JM, et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science. 2019; 364:eaaw4295.

[466] Kubach J, Lutter P, Bopp T, Stoll S, Becker C, Huter E, et al. Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin—10 as a novel marker essential for their anergy and suppressive function. Blood. 2007; 110:1550—8.

[467] Ackerman SJ, Liu L, Kwatia MA, Savage MP, Leonidas DD, Swaminathan GJ, et al. Charcot—Leyden crystal protein (galectin—10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem. 2002; 277:14859-68.

[468] Chua JC, Douglass JA, Gillman A, O’Hehir RE, Meeusen EN. Galectin—10, a potential biomarker of eosinophilic airway inflammation. PLoS One. 2012; 7:e42549.

[469] Bryborn M, Halldén C, Säll T, Cardell LO. CLC—a novel susceptibility gene for allergic rhinitis? Allergy. 2010; 65:220—8.

[470] Gelardi M, Giancaspro R, Cassano M. Charcot—Leyden crystals: An ancient but never so current discovery. Am J Otolaryngol. 2023; 44:103844.

[471] Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL—10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29:71-109.

[472] Mitre E, Klion AD. Eosinophils and helminth infection: protective or pathogenic? Semin Immunopathol. 2021; 43:363-81.

[473] Ackerman SJ, Stacy NI. Considerations on the evolutionary biology and functions of eosinophils: what the “haeckel”? J Leukoc Biol. 2024; 116:247-59.

[474] Rosario NA. Parasitic infections. Am J Dis Child. 1984; 138:507.

[475] Yates J. Parasitic Infections: Do Not Neglect Strongyloidiasis. Am Fam Physician. 2021; 104:224—5.

[476] Soil—transmitted helminth infections [Internet]. World Health Organization; [cited 2026 Jan 12]. Available from: https://www.who.int/news—room/fact—sheets/detail/soil—transmitted—helminth—infections

[477] Rosario Filho N, Carneiro Filho M, Ferreira E, Baranski MC, Cat I. Níveis de IgE total no soro e contagens de eosinófilos em crianças com enteroparasitoses: efeito do tratamento anti—helmíntico. J Pediatr (Rio J). 1982; 52:209—15. Portuguese.

[478] Phills JA, Harrold AJ, Whiteman GV, Perelmutter L. Pulmonary infiltrates, asthma and eosinophilia due to Ascaris suum infestation in man. N Engl J Med. 1972; 286:965—70.

[479] Rosario Filho NA. Total serum IgE levels and eosinophil counts in trichiuriasis. Rev Inst Med Trop Sao Paulo. 1982; 24:16-20.

[480] Agache I, Salazar J, Rodriguez—Tanta Y, Saenz FKF, Haahtela T, Traidl—Hoffmann C, et al. The Impact of Rhinovirus, Syncytial Respiratory Virus and Helminth Infection on the Risk of New—Onset Asthma and Other Allergic Conditions—A Systematic Review for the EAACI Guidelines on Environmental Science for Allergic Diseases and Asthma. Allergy. 2025; 80:1878-98.

[481] López JF, Zakzuk J, Satitsuksanoa P, Lozano A, Buergi L, Heider A, et al. Elevated circulating group—2 innate lymphoid cells expressing activation markers and correlated tryptase AB1 levels in active ascariasis. Front Immunol. 2024; 15:1459961.

[482] Zakzuk J, Lopez JF, Akdis C, Caraballo L, Akdis M, van de Veen W. Human Ascaris infection is associated with higher frequencies of IL—10 producing B cells. PLoS Negl Trop Dis. 2024; 18:e0012520.

[483] Grigg J, Barratt B, Bønnelykke K, Custovic A, Ege M, Pasquali C, et al. European Respiratory Society Research Seminar on Preventing Pediatric Asthma. Pediatr Pulmonol. 2025; 60:e27401.

[484] Cooper PJ, Chis Ster I, Chico ME, Vaca M, Oviedo Y, Maldonado A, et al. Impact of early life geohelminths on wheeze, asthma and atopy in Ecuadorian children at 8 years. Allergy. 2021; 76:2765—75.

[485] Taghipour A, Rostami A, Sepidarkish M, Ghaffarifar F. Is Ascaris lumbricoides a risk factor for development of asthma? A systematic review and meta—analysis. Microb Pathog. 2020; 142:104099.

[486] Cooper PJ, Chico ME, Vaca MG, Sandoval CA, Loor S, Amorim LD, et al. Effect of Early—Life Geohelminth Infections on the Development of Wheezing at 5 Years of Age. Am J Respir Crit Care Med. 2018; 197:364-72.

[487] Arrais M, Maricoto T, Nwaru BI, Cooper PJ, Gama JMR, Brito M, et al. Helminth infections and allergic diseases: Systematic review and meta—analysis of the global literature. J Allergy Clin Immunol. 2022; 149:2139-52.

[488] Ciprandi G, Cavallucci E, Cuccurullo F, Di Gioacchino M. Helminthic infection as a factor in new—onset coffee allergy in a father and daughter. J Allergy Clin Immunol. 2008; 121:773—4.

[489] Mpairwe H, Amoah AS. Parasites and allergy: Observations from Africa. Parasite Immunol. 2019; 41:e12589.

[490] Mohammadzadeh I, Darvish S, Riahi SM, Moghaddam SA, Pournasrollah M, Mohammadnia—Afrozi M, et al. Exposure to Toxocara spp. and Ascaris lumbricoides infections and risk of allergic rhinitis in children . Allergy Asthma Clin Immunol. 2020; 16:69.

[491] Cusack RP, Whetstone CE, Xie Y, Ranjbar M, Gauvreau GM. Regulation of Eosinophilia in Asthma—New Therapeutic Approaches for Asthma Treatment. Cells. 2021; 10:817.

[492] Pera V, Brusselle GG, Riemann S, Kors JA, Van Mulligen EM, Parry R, et al. Parasitic infections related to anti—type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS). Front Pharmacol. 2023; 14:1276340.

[493] Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria . Allergy. 2022; 77:734-66.

[494] Altrichter S, Frischbutter S, Fok JS, Kolkhir P, Jiao Q, Skov PS, et al. The role of eosinophils in chronic spontaneous urticaria. J Allergy Clin Immunol. 2020; 145:1510—6.

[495] Kolkhir P, Church MK, Altrichter S, Skov PS, Hawro T, Frischbutter S, et al. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. J Allergy Clin Immunol Pract. 2020; 8:318—25.

[496] Roth—Walter F. Iron—Deficiency in Atopic Diseases: Innate Immune Priming by Allergens and Siderophores. Front Allergy. 2022; 3:859922.

[497] Roth—Walter F, Adcock IM, Benito—Villalvilla C, Bianchini R, Bjermer L, Caramori G, et al. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology. Allergy. 2024; 79:1089-122.

[498] Vassilopoulou E, Venter C, Roth—Walter F. Malnutrition and Allergies: Tipping the Immune Balance towards Health. J Clin Med. 2024; 13:4713.

[499] Roth—Walter F, Berni Canani R, O’Mahony L, Peroni D, Sokolowska M, Vassilopoulou E, et al. Nutrition in chronic inflammatory conditions: Bypassing the mucosal block for micronutrients. Allergy. 2024; 79:353-83.

[500] Maazi H, Shirinbak S, Bloksma N, Nawijn MC, van Oosterhout AJM. Iron administration reduces airway hyperreactivity and eosinophilia in a mouse model of allergic asthma. Clin Exp Immunol. 2011; 166:80-6.

[501] Wen J, Wang C, Xia J, Giri M, Guo S. Relationship between serum iron and blood eosinophil counts in asthmatic adults: data from NHANES 2011—2018. Front Immunol. 2023; 14:1201160.

[502] Weigert R, Dosch NC, Bacsik—Campbell ME, Guilbert TW, Coe CL, Kling PJ. Maternal pregnancy weight gain and cord blood iron status are associated with eosinophilia in infancy. J Perinatol. 2015; 35:621-6.

[503] Petje LM, Jensen SA, Szikora S, Sulzbacher M, Bartosik T, Pjevac P, et al. Functional iron—deficiency in women with allergic rhinitis is associated with symptoms after nasal provocation and lack of iron—sequestering microbes. Allergy. 2021; 76:2882—6.

[504] Bartosik T, Jensen SA, Afify SM, Bianchini R, Hufnagl K, Hofstetter G, et al. Ameliorating Atopy by Compensating Micronutritional Deficiencies in Immune Cells: A Double—Blind Placebo—Controlled Pilot Study. J Allergy Clin Immunol Pract. 2022; 10:1889-902.

[505] Guarneri F, Guarneri C, Cannavò SP. Oral iron therapy and chronic idiopathic urticaria: sideropenic urticaria? Dermatol Ther. 2014; 27:223—6.

[506] Saini S, Jain AK, Agarwal S, Yadav D. Iron Deficiency and Pruritus: A Cross—Sectional Analysis to Assess Its Association and Relationship. Indian J Dermatol. 2021; 66:705.

[507] Wright JA, Richards T, Srai SKS. The role of iron in the skin and cutaneous wound healing. Front Pharmacol. 2014; 5:156.

[508] Grattan CEH, Kocatürk E. How relevant are eosinophils to chronic spontaneous urticaria? No evidence of clinical benefit from eosinophil depletion with benralizumab. Br J Dermatol. 2024; 191:153—4.

[509] Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony—stimulating factor and interleukin—5. Am J Respir Cell Mol Biol. 1997; 17:70-7.

[510] Davis MDP, Plager DA, George TJ, Weiss EA, Gleich GJ, Leiferman KM. Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol. 2003; 112:988-94.

[511] Zuberbier T, Ensina LF, Giménez—Arnau A, Grattan C, Kocatürk E, Kulthanan K, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024; 404:393-404.

[512] Oliver ET, Chichester K, Devine K, Sterba PM, Wegner C, Vonakis BM, et al. Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria. Int Arch Allergy Immunol. 2019; 179:21-30.

[513] Altrichter S, Giménez—Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, et al. ; ARROYO Study Investigators. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double—blind placebo—controlled ARROYO trial. Br J Dermatol. 2024; 191:187-99.

[514] Özen B, Sancakli O, Duman Senol H, Ozdogru EE, Tuncel T. An evaluation of the factors affecting the clinical and laboratory findings, prognosis, and treatment response in children with chronic urticaria. Dermatol Ther. 2022; 35:e15261.

[515] Sharma P, Shah A, Khanapara V, Sahu S, Jain A, Patidar T. Study of prevalence of iron deficiency anaemia in chronic urticaria. J Popul Ther Clin Pharmacol. 2024; 31:2875-80.

[516] Cevikbas F, Lerner EA. Physiology and Pathophysiology of Itch. Physiol Rev. 2020; 100:945-82.

[517] Ogulur I, Pat Y, Ardicli O, Barletta E, Cevhertas L, Fernandez—Santamaria R, et al. Advances and highlights in biomarkers of allergic diseases. Allergy. 2021; 76:3659—86.

[518] Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017; 140:335-48.

[519] Ramírez E, Medrano—Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, et al. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol. 2017; 83:400—15.

[520] Rijavec M, Maver A, Turner PJ, Hočevar K, Košnik M, Yamani A, et al. Integrative transcriptomic analysis in human and mouse model of anaphylaxis identifies gene signatures associated with cell movement, migration and neuroinflammatory signalling. Front Immunol. 2022; 13:1016165.

[521] Röntynen P, Kukkonen K, Savinko T, Mäkelä MJ. Interaction of mediators and effector cells in cashew nut—induced anaphylaxis. Ann Allergy Asthma Immunol. 2023; 131:239—52.

[522] Perskvist N, Edston E. Differential accumulation of pulmonary and cardiac mast cell—subsets and eosinophils between fatal anaphylaxis and asthma death: a postmortem comparative study. Forensic Sci Int. 2007; 169:43-9.

[523] Fineschi V, Cecchi R, Centini F, Reattelli LP, Turillazzi E. Immunohistochemical quantification of pulmonary mast—cells and post—mortem blood dosages of tryptase and eosinophil cationic protein in 48 heroin—related deaths. Forensic Sci Int. 2001; 120:189-94.

[524] Romano A, Fanales—Belasio E, Di Fonso M, Giuffreda F, Palmieri V, Zeppilli P, et al. Eosinophil—derived proteins in postprandial (food—dependent) exercise—induced anaphylaxis. Int Arch Allergy Immunol. 1997; 113:505—11.

[525] Gao H, Kosins AE, Ochoa JA, Jacobsen EA, Cook—Mills JM. Depletion of eosinophils during sensitization but not challenge phase in mice blocks the development of food allergy early in life. J Immunol. 2025; 214:582-94.

[526] Cardones AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol. 2020; 38:702—11.

[527] Kardaun SH, Sekula P, Valeyrie—Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013; 169:1071-80.

[528] Chen CB, Hung WK, Wang CW, Lee CC, Hung SI, Chung WH. Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review. Front Med (Lausanne). 2023; 10:1187937.

[529] Kang SY, Kim J, Ham J, Cho SH, Kang HR, Kim HY. Altered T cell and monocyte subsets in prolonged immune reconstitution inflammatory syndrome related with DRESS (drug reaction with eosinophilia and systemic symptoms). Asia Pac Allergy. 2020; 10:e2.

[530] Skowron F, Bensaid B, Balme B, Depaepe L, Kanitakis J, Nosbaum A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. J Eur Acad Dermatol Venereol. 2015; 29:2199-205.

[531] Schroeder JW, Napoli C, Caputo V, Bonoldi E, Rongioletti F. Unraveling the complexities of drug reaction with eosinophilia and systemic symptoms (DRESS): Insights into clinical, laboratory, and histopathologic features of a case series from an Italian tertiary center. Clin Dermatol. 2023; 41:721—8.

[532] Rubin L, Talmon A, Ribak Y, Kessler A, Martin Y, Haran TK, et al. Novel targeted inhibition of the IL—5 axis for drug reaction with eosinophilia and systemic symptoms syndrome. Front Immunol. 2023; 14:1134178.